Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Shares Outstanding (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Shares Outstanding for 8 consecutive years, with $32.9 million as the latest value for Q1 2025.

  • On a quarterly basis, Shares Outstanding changed N/A to $32.9 million in Q1 2025 year-over-year; TTM through Mar 2025 was $32.9 million, a N/A change, with the full-year FY2019 number at $66451.0, down 99.26% from a year prior.
  • Shares Outstanding was $32.9 million for Q1 2025 at Outlook Therapeutics, up from $24.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $32.9 million in Q1 2025 to a low of $24.9 million in Q4 2024.